Premium
In vitro and in vivo characterization of a high‐purity, solvent/detergent‐treated factor VIII concentrate: Evidence for its therapeutic efficacy in von Willebrand's disease
Author(s) -
Mazurier Claudine,
Romeuf Christophe,
ParquetGernez Armelle,
Goudemand Maurice
Publication year - 1989
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1989.tb01244.x
Subject(s) - von willebrand factor , von willebrand disease , in vivo , in vitro , chemistry , bleeding time , platelet , virus , immunology , pharmacology , medicine , microbiology and biotechnology , virology , biochemistry , biology , platelet aggregation
A factor VIII (FVIII) concentrate, virus‐inactivated by the solvent/detergent procedure, was studied in vitro. In contrast with most high‐purity, virus‐inactivated FVIII concentrates, it contains not only high levels of von Willebrand factor (vWF) antigen and ristocetin cofactor activity but also high molecular weight forms of von Willebrand factor. Furthermore, it is able to promote platelet adhesion on collagen in a perfusion system. In vivo studies performed in patients with different types of von Willebrand's disease provided evidence that this concentrate corrects Duke's bleeding time and prevents or stops haemorrhages. Thus, the particular advantages of this FVIII/vWF preparation are safety, low content of contamination proteins, and efficacy in von Willebrand's disease.